Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

OUD (Opioid Use Disorder) Target Trial

NCT06585709 · View on ClinicalTrials.gov ↗

Study Summary

In this research study the investigators will work with 80-participants with opioid use disorder who are starting treatment with the medication buprenorphine and are trying to quit using opioids. The investigators are trying to learn two things: 1. Can an MRI brain marker be used to predict which participants will be successful in quitting opioids with buprenorphine? 2. Does adjunctive treatment with repetitive Transcranial Magnetic Stimulation (rTMS) help people quit using opioids more than a sham (placebo) version of rTMS? In order to complete the study the investigators will ask participants to: * Complete an MRI within 5-days of starting buprenorphine and again after they are on a full stable dose 1-3 weeks later. * Undergo study-treatment with 30-sessions of either real or placebo rTMS in as little as 1-week (10-sessions-per-day for five days) or as long as over 6-weeks. * Meet with the investigators once per week over the following 12-weeks to see if the participants have been able to quit using opioids over that time.

Conditions Studied

Interventions

  • DEVICE Sham repetitive Transcranial Magnetic Stimulation (rTMS)
  • DEVICE Active repetitive Transcranial Magnetic Stimulation (rTMS)
  • DIAGNOSTIC_TEST High Ventral Striatal Reactivity
  • DIAGNOSTIC_TEST Low Ventral Striatal Reactivity

Study Locations (1)

North Carolina

  • Duke University — Durham

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2024-12-31
Est. Completion 2026-10-31
Phase NA

Sponsor

Duke University

1,129 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06585709

The ClinicalTrials.gov registry entry for NCT06585709 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,129 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 4 interventions — of which Sham repetitive Transcranial Magnetic Stimulation (rTMS) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06585709 reports 1 study location spanning 1 distinct geographic area — top geographies include North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06585709 about?

NCT06585709 is a clinical study titled "OUD (Opioid Use Disorder) Target Trial". In this research study the investigators will work with 80-participants with opioid use disorder who are starting treatment with the medication buprenorphine and are trying to quit using opioids. The investigators are trying to learn two things: 1. Can an MRI brain marker be used to predict which ...

What is the current status of trial NCT06585709?

This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2024-12-31. Estimated completion is 2026-10-31.

What conditions does trial NCT06585709 study?

This clinical trial studies the following conditions: Opioid Use Disorder. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06585709?

The interventions under investigation include: Sham repetitive Transcranial Magnetic Stimulation (rTMS) (DEVICE), Active repetitive Transcranial Magnetic Stimulation (rTMS) (DEVICE), High Ventral Striatal Reactivity (DIAGNOSTIC_TEST), Low Ventral Striatal Reactivity (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06585709?

This trial is sponsored by Duke University, which has 1,129 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06585709 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial